Aging, Diabete Mellitus, Metabolic Disorders, Randomized Controlled Trial, Traditional Chinese Medicine
Conditions
Brief summary
The primary objective of this clinical trial is to assess the clinical efficacy and safety of the Buyuan Zhixiao Formula in treating elderly patients with diabetes and multiple metabolic disorders exhibiting symptoms of renal deficiency and blood stasis. Furthermore, this study aims to intervene in high-risk factors to prevent arteriosclerosis and to investigate the clinical efficacy of the Buyuan Zhixiao Formula in the prevention and treatment of cognitive impairments. The main questions it aims to answer are: 1. What are the clinical effects of Buyuan Zhixiao Formula, including lowering blood sugar, lowering blood pressure, lowering lipids, and treating obesity? 2. Can Buyuan Zhixiao Formula improve cognitive impairment in diabetes? Researchers compared Buyuan Zhixiao Formula with a placebo (a drug that looks similar but contains only 10% of the active ingredients) to see if the drug Buyuan Zhixiao Formula can treat elderly people with diabetes and multiple metabolic disorders. Participants will: 1. Take the drug Bu Yuan Zhi XiaoFormula or placebo every day for 6 months；Follow-up for 6 months； 2. Check fasting blood sugar and 2-hour postprandial blood sugar every month; check HbA1c, blood lipids, vascular function, and cognitive impairment serum markers every 3 months; 3. Conduct scores on TCM symptoms, cognitive ability, nutritional status and other scales and adverse events; 4. Urine and serum samples were collected before and after treatment;
Interventions
DRUGBuyuan Zhixiao Formula
Buyuan Zhixiao Formula
DRUGPlacebo
The placebo contains 10% of the active ingredients of the Chinese medicine group
Sponsors
Qing Ni
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1.Age ≥65 years, irrespective of sex; * 2.Individuals who meet the Western medical diagnostic criteria for type 2 diabetes mellitus (T2DM) in the elderly, with a hemoglobin A1c level of ≥7.0% in the past three months; * 3.Compliance with the diagnostic criteria for abdominal obesity (waist circumference ≥90 cm for males and ≥85 cm for females); * 4.Conformity to the diagnostic standards for hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg); * 5.A history of dyslipidemia, where lipid levels have not reached the general control standards for elderly individuals with T2DM following oral lipid-lowering therapy (statins/bile acid sequestrants): LDL cholesterol \<2.6 mmol/L and/or triglycerides \<2.5 mmol/L; * 6.Diagnosis of kidney deficiency and blood stasis according to traditional Chinese medicine, with the pattern type referring to the《Guidelines for Clinical Research of New Chinese Medicines》; * 7.Willingness to sign an informed consent document.
Exclusion criteria
* 1.Exclusion of individuals who, within the past week, have experienced severe infections, acute cardiovascular or cerebrovascular events (such as acute cerebral infarction or myocardial infarction), significant trauma, acute pancreatitis, or other conditions that could precipitate stress-induced hyperglycemia. This also extends to those with concurrent endocrinopathies that may induce insulin resistance, such as Cushing's syndrome, hyperthyroidism, or pituitary growth hormone adenomas, as well as those currently receiving treatment with glucocorticoids or undergoing chemotherapy for malignancies. * 2.Exclusion of individuals with a history of neurological disorders or psychiatric conditions that could impair cognitive function, as well as those with a history of medication use for these conditions. * 3.Exclusion of individuals with severe complications of diabetes such as diabetic nephropathy in the uremic stage, or those with significant primary diseases of the cardiovascular, cerebrovascular, hepatic, renal, or hematopoietic systems, as well as individuals diagnosed with cancer. * 4.Exclusion of individuals with communication barriers that could affect the assessment of cognitive function, including severe impairments in speech, vision, and hearing. * 5.Individuals who have participated in other pharmacological clinical trials within the past month. * 6.Individuals who have insufficient understanding of this study, are unwilling to participate, or, based on the researchers' judgment, present a reduced likelihood of enrollment or poor compliance due to unstable work and living locations or other factors that could lead to loss to follow-up.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HbA1c | Measured at 0, 3, 6, and 12 months respectively. | unit：% |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Carotid Ultrasound; Carotid Intima-Media Thickness. | Measured at 0, 6, and 12 months | — |
| Concentration Variation of Von Willebrand Factor | Measured at 0, 3, 6, and 12 months | — |
| Measurement Results of Vascular Endothelial Growth Factor Levels at Different Time Points | Measured at 0, 3, 6, and 12 months | — |
| Change in Matrix Metalloproteinase-9 Levels or Participants' Matrix Metalloproteinase-9 Concentration | Measured at 0, 3, 6, and 12 months | — |
| Average Concentration of Soluble Intercellular Adhesion Molecule-1 | Measured at 0, 3, 6, and 12 months | — |
| Change in Serum Tau Protein Levels | Measured at 0, 3, 6, and 12 months | — |
| Average Concentration of Aβ40 | Measured at 0, 3, 6, and 12 months | — |
| Average Concentration of Aβ42 | Measured at 0, 3, 6, and 12 months | — |
| Fasting blood glucose | Measured at 0, 1, 2, 3, 4, 5, 6, 9, and 12 months respectively | unit：mmol/l |
| 2-hour postprandial blood glucose | Measured at 0, 1, 2, 3, 4, 5, 6, 9, and 12 months respectively | unit：mmol/l |
| blood pressure | Measured at 0, 1, 2, 3, 4, 5, 6, 9, and 12 months respectively | unit：mmHg |
| weight | Measured at 0, 1, 2, 3, 4, 5, 6, 9, and 12 months respectively | unit：KG |
| waist circumference | Measured at 0, 1, 2, 3, 4, 5, 6, 9, and 12 months respectively | unit：cm |
| BMI | Measured at 0, 1, 2, 3, 4, 5, 6, 9, and 12 months respectively | unit：kg/m2 |
| Total Cholesterol | Measured at 0, 3, 6, and 12 months | unit：mmol/l |
| Triglycerides | Measured at 0, 3, 6, and 12 months | unit：mmol/l |
| High density lipoprotein cholesterol | Measured at 0, 3, 6, and 12 months | unit：mmol/l |
| Low density lipoprotein cholesterol | Measured at 0, 3, 6, and 12 months | unit：mmol/l |
| Change in Neurofilament Light Chain Protein Levels | Measured at 0, 3, 6, and 12 months | — |
| Fasting insulin | Measured at 0, 3, 6, and 12 months | unit：pmol/L |
| C-peptide | Measured at 0, 3, 6, and 12 months | unit：pmol/L |
| insulin resistance index | Measured at 0, 3, 6, and 12 months | — |
| islet β-cell function index | Measured at 0, 3, 6, and 12 months | — |
| lipid Lipid accumulation product | Measured at 0, 3, 6, and 12 months | — |
| visceral adiposity index | Measured at 0, 3, 6, and 12 months | — |
| Measurement Results of Tumor Necrosis Factor-alpha Levels at Different Time Points | Measured at 0, 3, 6, and 12 months | — |
| Concentration Variation of Interleukin-10 | Measured at 0, 3, 6, and 12 months | — |
| Change in Homocysteine Levels | Measured at 0, 3, 6, and 12 months | — |
| Average Concentration of Interleukin-6 | Measured at 0, 3, 6, and 12 months | — |
| Change in Endothelin-1 Levels | Measured at 0, 3, 6, and 12 months | — |
| Average Concentration of Nitric Oxide | Measured at 0, 3, 6, and 12 months | — |
| Activities of Daily Living Scale score; Fried Frailty Phenotype Scale; Mini Nutritional Rating Scale; MoCA scale score; Traditional Chinese Medicine Kidney Deficiency and Blood Stasis Syndrome Scale score. | Measured at 0, 3, 6, and 12 months | — |
| Montreal Cognitive Assessment Score | Measured at 0, 3, 6, and 12 months | The maximum score is 30 points, and the higher the score, the better the cognitive function. |
| Fried Frailty Phenotype Scale | Measured at 0, 3, 6, and 12 months | Those who have 5 or more of the items in the table can be diagnosed as frailty syndrome; those with less than 3 items are in the early stage of frailty; 0 items are healthy elderly people without frailty. |
| Activities of Daily Living Scale score | Measured at 0, 3, 6, and 12 months | The scale consists of 10 items, with a total score of 100 points. The Cronbach's alpha of the scale is 0.813. A score of 100 points is considered normal, while scores below 100 indicate a decline.A score of 100 points indicates full independence in daily living, without any dependency; 61-99 points suggest mild dependency; 41-60 points indicate moderate dependency; ≤40 points denote severe dependency. |
| Mini Nutritional Rating Scale | Measured at 0, 3, 6, and 12 months | The total score is 14 points, with the Cronbach's alpha of the scale being 0.906. A score of ≤7 points is considered malnourished, 8-11 points indicate a risk of malnutrition, and 12-14 points are indicative of normal nutrition. The total score is 14 points, with the Cronbach's alpha of the scale being 0.906. A score of ≤7 points is considered malnourished, 8-11 points indicate a risk of malnutrition, and 12-14 points are indicative of normal nutrition. |
| Serum and urine metabolomics | Measured at 0 and 6 months respectively | Inferring the potential biological mechanisms of the effect of Buyuan Zhixiao Formula based on the differences in metabolic products in the blood and urine between the experimental and control groups. |
| Ankle-Brachial Index（ABI） | Measured at 0, 3, 6, and 12 months | The normal range for the ABI is generally considered to be from 0.9 to 1.3. |
Countries
China
Contacts
Primary ContactQing Ni, postgraduate
Backup Contactzhige Wen, postgraduate
Outcome results
None listed